Safety of intermediate dose of low molecular weight heparin in COVID-19 patients

Coagulopathy represents one of the most important determinants of morbidity and mortality in coronavirus disease-19 (COVID-19). Whether standard thromboprophylaxis is sufficient or higher doses are needed, especially in severe patients, is unknown. To evaluate the safety of intermediate dose regimen...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Thromb Thrombolysis
Hoofdauteurs: Mattioli, Massimo, Benfaremo, Devis, Mancini, Mauro, Mucci, Luciano, Mainquà, Paola, Polenta, Antonio, Baldini, Patrizia Maria, Fulgenzi, Francesca, Dennetta, Donatella, Bedetta, Samuele, Gasperoni, Lorenzo, Caraffa, Alessandro, Frausini, Gabriele
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Springer US 2020
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7426007/
https://ncbi.nlm.nih.gov/pubmed/32794132
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11239-020-02243-z
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items